Sensome have developed a revolutionary sensor technology that turns invasive medical devices into connected healthcare devices. The company’s sensing technology combines impedance-based micro-sensors with machine learning algorithms to instantly identify biological tissues upon contact with an unequaled predictive reliability.
In January of 2020, Sensome raised $9 Million B Round with equity investment from Asahi Intecc, which will go towards testing the clinical performance of their first product, the Clotild® connected guidewire which will be used for the treatment of ischemic stroke. Ischemic stroke can now be treated by removing the clot blocking the brain blood vessel using mechanical thrombectomy devices. At the current moment, the clot is only successfully removed on the first attempt in one of every three cases, however Sensome's new technology will greatly increase their chance, as it will transform these guidewires with it's tissue sensor. Sensome's sensor technology can be deployed in multiple other medical fields, such as interventional cardiology and oncology.
About the founders/CEO:
Franz Bozsak founded Sensome in 2014.
Franz Bozsak has brought together a world-class team of scientists, engineers and doctors, renowned experts in their respective fields, to help him realize his vision of innovative connected vascular devices. Franz obtained his Ph.D. from Ecole polytechnique on the optimization of drug-eluting stents and is a graduate of the Stanford Ignite-X business program.